- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
This is an old revision of the document!
Paper - Immunostimulation in the era of the metagenome
Type: Paper
Authors: Amy D. Proal, Paul J. Albert, Greg P. Blaney M.D., Inge A. Lindseth, Chris Benediktsson and Trevor G Marshall PhD
Publication: Cellular & molecular immunology
Citation: long:21278764
See also: Preprint (full text)
<html> <!–<form> <a href=“http://autoimmunityresearch.org/preprints/Proal2010CellularMolecularImmunologyPreprint.pdf”><input type=“image” name=“Submit” value=“Download as PDF” src=“http://mpkb.org/_media/home/downloadpdf.gif”; class=“buttoncalc hide” /></a> </form>–>
<form> <a href=“http://autoimmunityresearch.org/preprints/Proal2010CellularMolecularImmunologyPreprint.pdf”><input type=“image” name=“Submit” value=“Download as PDF” src=“http://mpkb.org/_media/home/downloadpdf.gif”; class=“buttoncalc hide” /></a> </form>
</html>
Abstract
Microbes are increasingly being implicated in autoimmune disease. This calls for a re-evaluation of how these chronic inflammatory illnesses are routinely treated. The standard of care for autoimmune disease remains the use of medications that slow the immune response, while treatments aimed at eradicating microbes seek the exact opposite—stimulation of the innate immune responseThe body's first line of defense against intracellular and other pathogens. According to the Marshall Pathogenesis the innate immune system becomes disabled as patients develop chronic disease.. Immunostimulation is complicated by a cascade of sequelae, including exacerbated inflammationThe complex biological response of vascular tissues to harmful stimuli such as pathogens or damaged cells. It is a protective attempt by the organism to remove the injurious stimuli as well as initiate the healing process for the tissue., which occurs in response to microbial death. Over the past 8 years, we have collaborated with American and international clinical professionals to research a model-based treatment for inflammatory disease. This intervention, designed to stimulate the innate immune response, has required a reevaluation of disease progression and amelioration. Paramount is the inherent conflict between palliation and microbicidal efficacy. Increased microbicidal activity was experienced as immunopathologyA temporary increase in disease symptoms experienced by Marshall Protocol patients that results from the release of cytokines and endotoxins as disease-causing bacteria are killed.—a temporary worsening of symptoms. Further studies are needed, but they will require careful planning to manage this immunopathology.